Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

[Management of chronic hepatitis C in 2012 in Belgium].

Moreno C, Deltenre P.

Rev Med Brux. 2012 Sep;33(4):223-7. Review. French.

PMID:
23091925
2.

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.

Swiss Association for the Study of the Liver.

Swiss Med Wkly. 2012 Feb 24;142:w13516. doi: 10.4414/smw.2012.13516. Review.

3.

[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].

Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S.

Z Gastroenterol. 2012 Jan;50(1):57-72. doi: 10.1055/s-0031-1282015. Epub 2012 Jan 5. Review. German.

PMID:
22222799
4.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
5.

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions.

Teixeira R, Nascimento Yde A, Crespo D.

Braz J Infect Dis. 2013 Mar-Apr;17(2):194-204. doi: 10.1016/j.bjid.2012.10.010. Epub 2013 Mar 9. Review.

6.

Future of hepatitis C therapy: development of direct-acting antivirals.

Dore GJ, Matthews GV, Rockstroh J.

Curr Opin HIV AIDS. 2011 Nov;6(6):508-13. doi: 10.1097/COH.0b013e32834b87f8. Review.

PMID:
21897228
7.

Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.

Butt AA, Kanwal F.

Clin Infect Dis. 2012 Jan 1;54(1):96-104. doi: 10.1093/cid/cir774. Epub 2011 Dec 7. Review.

PMID:
22156853
8.

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.

Leroy V, Serfaty L, Bourlière M, Bronowicki JP, Delasalle P, Pariente A, Pol S, Zoulim F, Pageaux GP; French Association for the Study of the Liver.

Liver Int. 2012 Nov;32(10):1477-92. doi: 10.1111/j.1478-3231.2012.02856.x. Epub 2012 Aug 14. Review.

PMID:
22891751
9.

New pharmacotherapy for hepatitis C.

Assis DN, Lim JK.

Clin Pharmacol Ther. 2012 Sep;92(3):294-305. doi: 10.1038/clpt.2012.103. Epub 2012 Aug 1. Review.

PMID:
22850602
10.

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.

Welsch C, Jesudian A, Zeuzem S, Jacobson I.

Gut. 2012 May;61 Suppl 1:i36-46. doi: 10.1136/gutjnl-2012-302144. Review. Erratum in: Gut. 2012 Aug;61(8):1145.

PMID:
22504918
11.

Management issues in chronic viral hepatitis: hepatitis C.

Sievert W.

J Gastroenterol Hepatol. 2002 Apr;17(4):415-22. Review.

PMID:
11982722
12.

Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.

Trembling PM, Tanwar S, Dusheiko GM.

Expert Rev Anti Infect Ther. 2012 Mar;10(3):269-79. doi: 10.1586/eri.12.8. Review.

PMID:
22397560
13.

[New treatments for hepatitis C, which targets, what timeline?].

Goossens N, Negro F.

Rev Med Suisse. 2011 Sep 7;7(307):1683-8. French.

PMID:
21987876
14.

Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.

Seden K, Back D.

Curr Opin HIV AIDS. 2011 Nov;6(6):514-26. doi: 10.1097/COH.0b013e32834b54dc. Review.

PMID:
22001895
15.

Boceprevir.

[No authors listed]

Prescrire Int. 2012 Apr;21(126):89-92.

PMID:
22515132
16.

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.

Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J.

J Viral Hepat. 2012 May;19 Suppl 2:1-26. doi: 10.1111/j.1365-2893.2012.01590.x. Review.

PMID:
22404758
17.

[Efficacy and safety of a protease inhibitor with pegylated interferon and ribavirin in patients with untreated chronic hepatitis C: a meta analysis].

Yuan XL, Li MY, Zhang DZ.

Zhonghua Gan Zang Bing Za Zhi. 2012 May;20(5):357-62. doi: 10.3760/cma.j.issn.1007-3418.2012.05.011. Chinese.

PMID:
22971281
18.

Treatment of chronic hepatitis C virus infection - Dutch national guidelines.

de Bruijne J, Buster EH, Gelderblom HC, Brouwer JT, de Knegt RJ, van Erpecum KJ, Schalm SW, Bakker CM, Zaaijer HL, Janssen HL, Reesink HW; Netherlands Association of Gastroenterologists and Hepatologists.

Neth J Med. 2008 Jul-Aug;66(7):311-22. Review. Erratum in: Neth J Med. 2008 Dec;66(11):456. Dosage error in article text.

19.

Telaprevir: an oral protease inhibitor for hepatitis C virus infection.

Kim JJ, Culley CM, Mohammad RA.

Am J Health Syst Pharm. 2012 Jan 1;69(1):19-33. doi: 10.2146/ajhp110123. Review.

PMID:
22180548
20.

New developments in HCV therapy.

Kronenberger B, Zeuzem S.

J Viral Hepat. 2012 Jan;19 Suppl 1:48-51. doi: 10.1111/j.1365-2893.2011.01526.x.

PMID:
22233414

Supplemental Content

Support Center